Recent studies have supported the use of the IL‐6R inhibitor tocilizumab,40 and the use of colchicine in COVID‐1947 was associated with the reduction of multiple inflammatory mediators, including CRP, IL‐6, resistin, and vascular proteins in obesity. This evidence concerns the gene IL6R and Obesity.